LXRP News and Press, Lexaria Bioscience Corp. From 12/07/20

-Benzinga Global Small Cap Conference on December 8 th -LD Micro Main Event on Dec 15 th -H.C. Wainwright BioConnect, held on Jan 11-14 -Virtual Biotech Showcase, held on Jan 11-14 KELOWNA, BC / ACCESSWIRE / December 7, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Compa...

(TheNewswire) - Benzinga Global Small Cap Conference on December 8 th - LD Micro Main Event on Dec 15 th - H.C. Wainwright BioConnect, held on Jan 11-14 - Virtual Biotech Showcase, held on Jan 11-14 Kelowna, Br...

Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19 KELOWNA, BC / ACCESSWIRE / December 1, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delive...

Lexaria Bioscience (LXRP) has entered a definitive asset purchase agreement, through its wholly owned subsidiary Lexaria Canpharm, to sell certain non-core, non-pharmaceutical THC-related business assets for gross proceeds of C$3.85M (~$2.85M) to LXRP's long-standing Canadian licensee Hill St...

Asset Sale in Preparation for US National Securities Exchange Listing KELOWNA, BC / ACCESSWIRE / November 19, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has entered a definitive asset purchase a...

Phoenix, Arizona--(Newsfile Corp. - November 17, 2020) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (OTCQX: LXRP) ("the Company"), known for its proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the blo...

(TheNewswire) Lexaria Focusing on Four Core Business Segments: - Heart disease including hypertension - Reduced-risk non combusted nicotine - Improved antiviral drug delivery - CBD from hemp Kelowna, British Columbia ...

KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were i...

Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021 KELOWNA, BC / ACCESSWIRE / October 22, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, is pleased to announce that it is e...

Lexaria Bioscience (LXRP) receives its first-ever granted patent in Europe related to its DehydraTECHTM technology. European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled "Food and Beverage Compositions Infused With Lipophilic Activ...